JP7449283B2 - ビアリール誘導体 - Google Patents
ビアリール誘導体 Download PDFInfo
- Publication number
- JP7449283B2 JP7449283B2 JP2021520916A JP2021520916A JP7449283B2 JP 7449283 B2 JP7449283 B2 JP 7449283B2 JP 2021520916 A JP2021520916 A JP 2021520916A JP 2021520916 A JP2021520916 A JP 2021520916A JP 7449283 B2 JP7449283 B2 JP 7449283B2
- Authority
- JP
- Japan
- Prior art keywords
- biphenyl
- amino
- group
- calcification
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000005841 biaryl group Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 161
- 208000004434 Calcinosis Diseases 0.000 claims description 61
- 230000002308 calcification Effects 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 55
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 claims description 24
- 208000005475 Vascular calcification Diseases 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 230000011164 ossification Effects 0.000 claims description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 208000020832 chronic kidney disease Diseases 0.000 claims description 14
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 claims description 13
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 claims description 13
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 210000004446 longitudinal ligament Anatomy 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 10
- 206010051714 Calciphylaxis Diseases 0.000 claims description 9
- 206010002906 aortic stenosis Diseases 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 210000004749 ligamentum flavum Anatomy 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000009885 systemic effect Effects 0.000 claims description 9
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 208000019408 hereditary arterial and articular multiple calcification syndrome Diseases 0.000 claims description 7
- 201000000523 end stage renal failure Diseases 0.000 claims description 5
- 208000029497 Elastoma Diseases 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 3
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- JLTPSDHKZGWXTD-UHFFFAOYSA-N 2-[6-(dicyanomethylidene)naphthalen-2-ylidene]propanedinitrile Chemical compound N#CC(C#N)=C1C=CC2=CC(=C(C#N)C#N)C=CC2=C1 JLTPSDHKZGWXTD-UHFFFAOYSA-N 0.000 claims 2
- 101710161969 Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 claims 2
- -1 biaryl compounds Chemical class 0.000 description 127
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 49
- 239000000243 solution Substances 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 37
- 238000012360 testing method Methods 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 239000002585 base Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 235000010290 biphenyl Nutrition 0.000 description 14
- 235000011054 acetic acid Nutrition 0.000 description 13
- 229960000583 acetic acid Drugs 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000012156 elution solvent Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 125000003831 tetrazolyl group Chemical group 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 102100029177 PDZ and LIM domain protein 3 Human genes 0.000 description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 201000008482 osteoarthritis Diseases 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 7
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000004040 coloring Methods 0.000 description 7
- 201000010095 craniometaphyseal dysplasia Diseases 0.000 description 7
- 150000002170 ethers Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 208000034970 Heterotopic Ossification Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000007941 heterotopic ossification Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 5
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 5
- 206010023198 Joint ankylosis Diseases 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 102100022464 5'-nucleotidase Human genes 0.000 description 4
- MSJZQOHFAWAQMR-UHFFFAOYSA-N 5-methylpyridine-3-sulfonyl chloride Chemical compound CC1=CN=CC(S(Cl)(=O)=O)=C1 MSJZQOHFAWAQMR-UHFFFAOYSA-N 0.000 description 4
- 208000027896 Aortic valve disease Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 4
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 4
- 206010021263 IgA nephropathy Diseases 0.000 description 4
- 208000011200 Kawasaki disease Diseases 0.000 description 4
- 208000003397 Keutel syndrome Diseases 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- 239000012901 Milli-Q water Substances 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical class CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 208000010191 Osteitis Deformans Diseases 0.000 description 4
- 208000027067 Paget disease of bone Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000005529 alkyleneoxy group Chemical group 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 4
- 208000016738 bone Paget disease Diseases 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical class CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 102000045328 human ALPL Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 208000008494 pericarditis Diseases 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 210000002465 tibial artery Anatomy 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- ROJHLIXFJVDKFP-UHFFFAOYSA-N 2-[4-[5-chloro-2-[(4,5-dimethylpyridin-3-yl)sulfonylamino]-3-fluorophenyl]phenoxy]-2-methylpropanoic acid Chemical compound O(C(C(=O)O)(C)C)C1=CC=C(C2=CC(Cl)=CC(F)=C2NS(=O)(=O)C2=C(C)C(C)=CN=C2)C=C1 ROJHLIXFJVDKFP-UHFFFAOYSA-N 0.000 description 3
- HBHBARSMRVAINH-UHFFFAOYSA-N 2-bromo-4-chloro-6-fluoroaniline Chemical compound NC1=C(F)C=C(Cl)C=C1Br HBHBARSMRVAINH-UHFFFAOYSA-N 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- JWSTZQCMWBCPCW-UHFFFAOYSA-N CC(C)(C(O)=O)OC(C=C1)=CC=C1C(C=C(C=C1Cl)Cl)=C1NS(C1=CC(C)=CN=C1)(=O)=O Chemical compound CC(C)(C(O)=O)OC(C=C1)=CC=C1C(C=C(C=C1Cl)Cl)=C1NS(C1=CC(C)=CN=C1)(=O)=O JWSTZQCMWBCPCW-UHFFFAOYSA-N 0.000 description 3
- AHOSTXABXMMRJZ-UHFFFAOYSA-N CC1=CN=CC(S(N(C(C(F)=CC(Cl)=C2)=C2C(C=C2)=CC=C2OCC2=NN(C3OCCCC3)N=N2)S(C2=CC(C)=CN=C2)(=O)=O)(=O)=O)=C1 Chemical compound CC1=CN=CC(S(N(C(C(F)=CC(Cl)=C2)=C2C(C=C2)=CC=C2OCC2=NN(C3OCCCC3)N=N2)S(C2=CC(C)=CN=C2)(=O)=O)(=O)=O)=C1 AHOSTXABXMMRJZ-UHFFFAOYSA-N 0.000 description 3
- DRGHXVOWWRBZMG-UHFFFAOYSA-N ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)OCC=1N=NNN=1)NS(=O)(=O)C=1C=NC=C(C=1)C)F Chemical compound ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)OCC=1N=NNN=1)NS(=O)(=O)C=1C=NC=C(C=1)C)F DRGHXVOWWRBZMG-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 101000688216 Homo sapiens Intestinal-type alkaline phosphatase Proteins 0.000 description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 3
- 101000616014 Homo sapiens Magnesium transporter protein 1 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 206010043255 Tendonitis Diseases 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 150000005347 biaryls Chemical class 0.000 description 3
- 125000000707 boryl group Chemical group B* 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 201000010934 exostosis Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 102000053119 human ALPI Human genes 0.000 description 3
- 201000010930 hyperostosis Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 208000025061 parathyroid hyperplasia Diseases 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000003460 sulfonic acids Chemical class 0.000 description 3
- 201000004415 tendinitis Diseases 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 2
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- DCTOHCCUXLBQMS-UHFFFAOYSA-N 1-undecene Chemical compound CCCCCCCCCC=C DCTOHCCUXLBQMS-UHFFFAOYSA-N 0.000 description 2
- LRMSQVBRUNSOJL-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)F LRMSQVBRUNSOJL-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- LUVSQKLPVGDAHH-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(5-methylpyridin-3-yl)sulfonylamino]phenyl]-2-fluorophenoxy]-2-methylpropanoic acid Chemical compound ClC=1C=C(C(=C(C=1)C1=CC(=C(C=C1)OC(C(=O)O)(C)C)F)NS(=O)(=O)C=1C=NC=C(C=1)C)F LUVSQKLPVGDAHH-UHFFFAOYSA-N 0.000 description 2
- STFHQVGQUPVJFD-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(5-methylpyridin-3-yl)sulfonylamino]phenyl]phenoxy]-2-methylpropanoic acid Chemical compound O(C(C(=O)O)(C)C)C1=CC=C(C2=CC(Cl)=CC(F)=C2NS(=O)(=O)C2=CC(C)=CN=C2)C=C1 STFHQVGQUPVJFD-UHFFFAOYSA-N 0.000 description 2
- JPZOXWNWBAAVHJ-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(5-propan-2-yloxypyridin-3-yl)sulfonylamino]phenyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)OC(C(=O)O)(C)C)NS(=O)(=O)C=1C=NC=C(C=1)OC(C)C)F JPZOXWNWBAAVHJ-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- KGUZVLVORRVVIQ-UHFFFAOYSA-N 3-[4-[5-chloro-3-fluoro-2-[(5-propan-2-yloxypyridin-3-yl)sulfonylamino]phenyl]phenyl]propanoic acid Chemical compound ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)CCC(=O)O)NS(=O)(=O)C=1C=NC=C(C=1)OC(C)C)F KGUZVLVORRVVIQ-UHFFFAOYSA-N 0.000 description 2
- BICZJRAGTCRORZ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(O)C=C1 BICZJRAGTCRORZ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical class CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 2
- KKESBYDKFXCJBU-UHFFFAOYSA-N CCC1=CN=CC(S(NC(C(F)=CC(Cl)=C2)=C2C(C=C2)=CC=C2OC(C)(C)C(O)=O)(=O)=O)=C1 Chemical compound CCC1=CN=CC(S(NC(C(F)=CC(Cl)=C2)=C2C(C=C2)=CC=C2OC(C)(C)C(O)=O)(=O)=O)=C1 KKESBYDKFXCJBU-UHFFFAOYSA-N 0.000 description 2
- YJVBIWVBUGNQFL-UHFFFAOYSA-N CCOC(CN(C(OC(C)(C)C)=O)C(C=C1)=CC=C1C(C=C(C=C1F)Cl)=C1NS(C1=CC(C)=CN=C1)(=O)=O)=O Chemical compound CCOC(CN(C(OC(C)(C)C)=O)C(C=C1)=CC=C1C(C=C(C=C1F)Cl)=C1NS(C1=CC(C)=CN=C1)(=O)=O)=O YJVBIWVBUGNQFL-UHFFFAOYSA-N 0.000 description 2
- 238000003650 Calcium Assay Kit Methods 0.000 description 2
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 2
- ZCUWUAOIMXDEBJ-UHFFFAOYSA-N ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)OCC=1N=NN(N=1)C1OCCCC1)NS(=O)(=O)C=1C=NC=C(C=1)C)F Chemical compound ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)OCC=1N=NN(N=1)C1OCCCC1)NS(=O)(=O)C=1C=NC=C(C=1)C)F ZCUWUAOIMXDEBJ-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000033173 Generalized arterial calcification of infancy Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000730648 Homo sapiens Phospholipase A-2-activating protein Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PQXCQHKAKFKSBC-UHFFFAOYSA-N N-[2,4-dichloro-6-(3-fluoro-4-methylsulfonylphenyl)phenyl]-5-methoxypyridine-3-sulfonamide Chemical compound ClC=1C(=C(C=C(C=1)Cl)C1=CC(=C(C=C1)S(=O)(=O)C)F)NS(=O)(=O)C=1C=NC=C(C=1)OC PQXCQHKAKFKSBC-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 208000004900 arterial calcification of infancy Diseases 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical group [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- IQZKSHUYUUYHED-UHFFFAOYSA-N ethyl 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propanoate Chemical compound C1=CC(OC(C)(C)C(=O)OCC)=CC=C1B1OC(C)(C)C(C)(C)O1 IQZKSHUYUUYHED-UHFFFAOYSA-N 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005155 haloalkylene group Chemical group 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008011 inorganic excipient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000008012 organic excipient Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- CDRNYKLYADJTMN-UHFFFAOYSA-N pyridine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CN=C1 CDRNYKLYADJTMN-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003752 saphenous vein Anatomy 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical class CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 1
- TXIPVVLKTCCGPA-UHFFFAOYSA-N 2-[3-[2-[[1-(cyclopropanecarbonyl)piperidin-3-yl]amino]pyrimidin-4-yl]-2-quinolin-2-ylimidazol-4-yl]acetonitrile Chemical compound C1(CC1)C(=O)N1CC(CCC1)NC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=NC2=CC=CC=C2C=C1 TXIPVVLKTCCGPA-UHFFFAOYSA-N 0.000 description 1
- YSUCKRBJDGPBAX-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(4-methoxypyridin-3-yl)sulfonylamino]phenyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)OC(C(=O)O)(C)C)NS(=O)(=O)C=1C=NC=CC=1OC)F YSUCKRBJDGPBAX-UHFFFAOYSA-N 0.000 description 1
- GYYJGWHDDCMUAS-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(4-methylpyrimidin-5-yl)sulfonylamino]phenyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)OC(C(=O)O)(C)C)NS(=O)(=O)C=1C(=NC=NC=1)C)F GYYJGWHDDCMUAS-UHFFFAOYSA-N 0.000 description 1
- SAOOAPCAGGCWCF-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(5-methoxypyridin-3-yl)sulfonylamino]phenyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)OC(C(=O)O)(C)C)NS(=O)(=O)C=1C=NC=C(C=1)OC)F SAOOAPCAGGCWCF-UHFFFAOYSA-N 0.000 description 1
- YTNYMRSOEOBDIZ-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(5-methylpyridin-3-yl)sulfonylamino]phenyl]anilino]acetic acid Chemical compound CC1=CC(=CN=C1)S(=O)(=O)NC2=C(C=C(C=C2F)Cl)C3=CC=C(C=C3)NCC(=O)O YTNYMRSOEOBDIZ-UHFFFAOYSA-N 0.000 description 1
- FIXLEEQWNMUPJC-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(5-methylpyridin-3-yl)sulfonylamino]phenyl]phenyl]acetic acid Chemical compound ClC=1C=C(C(=C(C=1)C1=CC=C(C=C1)CC(=O)O)NS(=O)(=O)C=1C=NC=C(C=1)C)F FIXLEEQWNMUPJC-UHFFFAOYSA-N 0.000 description 1
- JXADJXXIZLGGPK-UHFFFAOYSA-N 2-[4-[5-chloro-3-fluoro-2-[(5-methylsulfonylpyridin-3-yl)sulfonylamino]phenyl]phenoxy]-2-methylpropanoic acid Chemical compound CC(C)(C(=O)O)OC1=CC=C(C=C1)C2=C(C(=CC(=C2)Cl)F)NS(=O)(=O)C3=CN=CC(=C3)S(=O)(=O)C JXADJXXIZLGGPK-UHFFFAOYSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- DTPADCOGQUOGHT-UHFFFAOYSA-N 2-bromo-4,6-dichloroaniline Chemical compound NC1=C(Cl)C=C(Cl)C=C1Br DTPADCOGQUOGHT-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004913 2-ethylbutylamino group Chemical group C(C)C(CN*)CC 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical class CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- HYEKNILQTURNLX-UHFFFAOYSA-N 3-[4-[5-chloro-2-[(4,5-dimethylpyridin-3-yl)sulfonylamino]-3-fluorophenyl]phenyl]propanoic acid Chemical compound CC1=CN=CC(=C1C)S(=O)(=O)NC2=C(C=C(C=C2F)Cl)C3=CC=C(C=C3)CCC(=O)O HYEKNILQTURNLX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- KOLAPUNNETTYLH-UHFFFAOYSA-N 4,5-dimethylpyridine-3-sulfonyl chloride Chemical compound Cc1cncc(c1C)S(Cl)(=O)=O KOLAPUNNETTYLH-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- AGWSISOYPHROLN-UHFFFAOYSA-N 5-(chloromethyl)-2h-tetrazole Chemical compound ClCC=1N=NNN=1 AGWSISOYPHROLN-UHFFFAOYSA-N 0.000 description 1
- SNSBIMPFYIEINH-UHFFFAOYSA-N 5-ethylpyridine-3-sulfonyl chloride Chemical compound CCC1=CN=CC(S(Cl)(=O)=O)=C1 SNSBIMPFYIEINH-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- KCDIHKJCUOYJMM-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N(CC(=O)OCC)C1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C Chemical compound C(C)(C)(C)OC(=O)N(CC(=O)OCC)C1=CC=C(C=C1)B1OC(C(O1)(C)C)(C)C KCDIHKJCUOYJMM-UHFFFAOYSA-N 0.000 description 1
- ZFWBVTIVJAFUDI-UHFFFAOYSA-N C(C)OC(CNC1=CC=C(C=C1)C1=C(C(=CC(=C1)Cl)F)NS(=O)(=O)C=1C=NC=C(C1)C)=O Chemical compound C(C)OC(CNC1=CC=C(C=C1)C1=C(C(=CC(=C1)Cl)F)NS(=O)(=O)C=1C=NC=C(C1)C)=O ZFWBVTIVJAFUDI-UHFFFAOYSA-N 0.000 description 1
- VWCCKHDPMNGBLH-UHFFFAOYSA-M CC(C)(C([O-])=O)OC(C=C1)=CC=C1C(C=C(C=C1F)Cl)=C1NS(C1=C(C)C(C)=CN=C1)(=O)=O.[K+] Chemical compound CC(C)(C([O-])=O)OC(C=C1)=CC=C1C(C=C(C=C1F)Cl)=C1NS(C1=C(C)C(C)=CN=C1)(=O)=O.[K+] VWCCKHDPMNGBLH-UHFFFAOYSA-M 0.000 description 1
- MYJZNWJOIUEVKX-UHFFFAOYSA-M CC(C)(C([O-])=O)OC(C=C1)=CC=C1C(C=C(C=C1F)Cl)=C1NS(C1=C(C)C(C)=CN=C1)(=O)=O.[Na+] Chemical compound CC(C)(C([O-])=O)OC(C=C1)=CC=C1C(C=C(C=C1F)Cl)=C1NS(C1=C(C)C(C)=CN=C1)(=O)=O.[Na+] MYJZNWJOIUEVKX-UHFFFAOYSA-M 0.000 description 1
- HVCXBMBGQMVUIY-UHFFFAOYSA-N CC1=CN=CC(S(NC(C(F)=CC(Cl)=C2)=C2C2=CC=C(CC(O)=O)C=C2)(=O)=O)=C1C Chemical compound CC1=CN=CC(S(NC(C(F)=CC(Cl)=C2)=C2C2=CC=C(CC(O)=O)C=C2)(=O)=O)=C1C HVCXBMBGQMVUIY-UHFFFAOYSA-N 0.000 description 1
- DVXREFMSMLHIRW-UHFFFAOYSA-N CCC(C=CN=C1)=C1S(NC(C(F)=CC(Cl)=C1)=C1C(C=C1)=CC=C1OC(C)(C)C(O)=O)(=O)=O Chemical compound CCC(C=CN=C1)=C1S(NC(C(F)=CC(Cl)=C1)=C1C(C=C1)=CC=C1OC(C)(C)C(O)=O)(=O)=O DVXREFMSMLHIRW-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- DPZYEVZAVOCHBX-UHFFFAOYSA-N CCOC(CCC(C=C1)=CC=C1C(C=C(C=C1F)Cl)=C1N)=O Chemical compound CCOC(CCC(C=C1)=CC=C1C(C=C(C=C1F)Cl)=C1N)=O DPZYEVZAVOCHBX-UHFFFAOYSA-N 0.000 description 1
- FFRCXKOQXDDJKN-UHFFFAOYSA-N COC(COC(C=C1)=CC=C1C(C=C(C=C1Cl)Cl)=C1NS(C1=CC=CN=C1)(=O)=O)=O Chemical compound COC(COC(C=C1)=CC=C1C(C=C(C=C1Cl)Cl)=C1NS(C1=CC=CN=C1)(=O)=O)=O FFRCXKOQXDDJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- OSTDXCZSWICKAE-UHFFFAOYSA-N ClC1=CC(=C(C(=C1)C1=CC=C(C=C1)OCC=1N=NN(N=1)C1OCCCC1)N)F Chemical compound ClC1=CC(=C(C(=C1)C1=CC=C(C=C1)OCC=1N=NN(N=1)C1OCCCC1)N)F OSTDXCZSWICKAE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- ALUASVJPSGCLTJ-UHFFFAOYSA-N NC1=C(C=C(C=C1Cl)Cl)C1=CC=C(C=C1)OC(C(=O)OCC)(C)C Chemical compound NC1=C(C=C(C=C1Cl)Cl)C1=CC=C(C=C1)OC(C(=O)OCC)(C)C ALUASVJPSGCLTJ-UHFFFAOYSA-N 0.000 description 1
- PKPBGUBUPHWRLH-UHFFFAOYSA-N NC1=C(C=C(C=C1Cl)Cl)C1=CC=C(OCC(=O)OC)C=C1 Chemical compound NC1=C(C=C(C=C1Cl)Cl)C1=CC=C(OCC(=O)OC)C=C1 PKPBGUBUPHWRLH-UHFFFAOYSA-N 0.000 description 1
- HPZPBUYOFNQESQ-UHFFFAOYSA-N NC1=C(C=C(C=C1F)Cl)C1=CC=C(C=C1)OC(C(=O)OCC)(C)C Chemical compound NC1=C(C=C(C=C1F)Cl)C1=CC=C(C=C1)OC(C(=O)OCC)(C)C HPZPBUYOFNQESQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- PRCOGZNDLWXGHB-UHFFFAOYSA-N [4-(3-ethoxy-3-oxopropyl)phenyl]boronic acid Chemical compound CCOC(=O)CCC1=CC=C(B(O)O)C=C1 PRCOGZNDLWXGHB-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000007047 acrodysostosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 201000006800 aortic valve disease 1 Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 230000002176 calcinogenic effect Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 159000000006 cesium salts Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- MVONGXQEOJETFB-UHFFFAOYSA-N ethyl 2-[4-(2-amino-5-chloro-3-fluorophenyl)-N-[(2-methylpropan-2-yl)oxycarbonyl]anilino]acetate Chemical compound NC1=C(C=C(C=C1F)Cl)C1=CC=C(C=C1)N(CC(=O)OCC)C(=O)OC(C)(C)C MVONGXQEOJETFB-UHFFFAOYSA-N 0.000 description 1
- ROCLHFSUEZTYIQ-UHFFFAOYSA-N ethyl 2-[4-(2-amino-5-chloro-3-fluorophenyl)phenyl]acetate Chemical compound NC1=C(C=C(C=C1F)Cl)C1=CC=C(C=C1)CC(=O)OCC ROCLHFSUEZTYIQ-UHFFFAOYSA-N 0.000 description 1
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 1
- MFFXVVHUKRKXCI-UHFFFAOYSA-N ethyl iodoacetate Chemical compound CCOC(=O)CI MFFXVVHUKRKXCI-UHFFFAOYSA-N 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019860 lauric fat Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- UPRXAOPZPSAYHF-UHFFFAOYSA-N lithium;cyclohexyl(propan-2-yl)azanide Chemical compound CC(C)N([Li])C1CCCCC1 UPRXAOPZPSAYHF-UHFFFAOYSA-N 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- YSMZEMQBSONIMJ-UHFFFAOYSA-M magnesium;2-methanidylpropane;chloride Chemical compound [Mg+2].[Cl-].CC(C)[CH2-] YSMZEMQBSONIMJ-UHFFFAOYSA-M 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 1
- QQAQUAGZYRTGAB-UHFFFAOYSA-N methyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1B1OC(C)(C)C(C)(C)O1 QQAQUAGZYRTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003941 n-butylamines Chemical class 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- YLLIGHVCTUPGEH-UHFFFAOYSA-M potassium;ethanol;hydroxide Chemical compound [OH-].[K+].CCO YLLIGHVCTUPGEH-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical class CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HSJNIOYPTSKQBD-UHFFFAOYSA-N tert-butyl n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1B1OC(C)(C)C(C)(C)O1 HSJNIOYPTSKQBD-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- RIAJLMJRHLGNMZ-UHFFFAOYSA-N triazanium;trioxomolybdenum;phosphate Chemical compound [NH4+].[NH4+].[NH4+].O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.[O-]P([O-])([O-])=O RIAJLMJRHLGNMZ-UHFFFAOYSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
本出願は、2018年10月23日に出願された米国特許出願第62/749,590号の利益を主張するものであり、その全体が参照によって明示的にここに組み込まれる。
本発明は、優れた組織非特異型アルカリホスファターゼ(tissuenon-specific alkaline phosphatase、以下、TNAP)阻害活性を有する新規なビアリール誘導体又はその薬理上許容される塩に関する。
生体内における石灰化は、骨芽細胞と破骨細胞の活性化バランス、血中リン・カルシウム濃度、及びそれらの濃度の恒常性を維持するために分泌される副甲状腺ホルモン又はビタミンDによって厳密に調節されている(非特許文献1)。異所性石灰化は、例えば、弾性線維性仮性黄色腫(PXE)、乳児全身性動脈石灰化(GACI)、頭蓋骨幹端異形成症(CMD)、黄色靭帯骨化症(OYL)、CD73欠損性動脈石灰化(ACDC)、関節と動脈の石灰化(CALJA)、変形性関節症、骨関節炎、関節強直症、特発性乳児動脈石灰化(IIAC)、強直性脊椎炎(AS)、腫瘍性石灰沈着症(TC)、進行性骨異形成(POH)、Keutel症候群、慢性腎不全(糸球体腎炎、IgA腎症、高血圧性腎症および糖尿病性腎症を含む)と二次性副甲状腺過形成に伴う血管石灰化、転移性石灰化、カルシフィラキシス、石灰沈着性頚長筋炎、進行性骨化性線維異形成症(FOP)、石灰化性大動脈弁狭窄症、石灰化性心膜炎、アテローム硬化性血管石灰化、尿毒症性細小動脈石灰化症(CUA)、川崎病、肥満性および加齢性石灰化、脛骨動脈石灰化、骨転移(bone metastasis)、人口装具関連性石灰化(prosthetic calcification)、骨ページェット病、特発性基底核石灰化症(IBGC)、異所性骨化(HO)、石灰化大動脈弁疾患(大動脈弁狭窄症)、石灰性腱炎、後縦靱帯骨化症(OPLL)、前縦靱帯骨化症(OALL)、広汎性特発性骨増殖症(DISH)、半月板石灰化、あるいは、腹膜石灰化等の疾患で認められる。これらの病態では前記調節機構が破綻することで本来起きるべきではない組織(血管、軟部組織など)に石灰化が起こり、活動制限による著しい生活の質(QOL)の低下と心血管系リスクの増大をもたらすことが知られている(非特許文献2、非特許文献3)。異所性石灰化には有効な治療薬が存在しない。そのためアンメットメディカルニーズが非常に高い疾患であると言える(非特許文献4)。
[1]
下記式(I):
[式中、X1は窒素原子又はCR9を示し、
R1は、水素原子、C1-C6アルキル基又はC1-C6アルコキシ基を示し、
R2は、ハロゲン原子を示し、
R3は、水素原子又はハロゲン原子を示し、
R4は、水素原子又はハロゲン原子を示し、
R5は、C1-C3アルキルスルホニル基、C1-C6アルキル基(該アルキル基は、C1-C3アルキルスルホニル基、カルボキシ基及びテトラゾリル基から選択される基で1つ置換されている)、C1-C6ハロアルキル基(該ハロアルキル基は、C1-C3アルキルスルホニル基、カルボキシ基及びテトラゾリル基から選択される基で1つ置換されている)、C1-C6アルコキシ基(該アルコキシ基は、C1-C3アルキルスルホニル基、カルボキシ基及びテトラゾリル基から選択される基で1つ置換されている)又はC1-C6アルキルアミノ基(該アルキルアミノ基は、C1-C3アルキルスルホニル基、カルボキシ基及びテトラゾリル基から選択される基で1つ置換されている)を示し、
R9は、水素原子、ハロゲン原子、C1-C3アルキルスルホニル基、C1-C6アルキル基又はC1-C6アルコキシ基を示す]
で表される化合物又はその薬理上許容される塩。
下記式(II):
[式中、R1は、水素原子又はC1-C3アルキル基を示し、
R2は、ハロゲン原子を示し、
R3は、ハロゲン原子を示し、
R5は、C1-C6アルキル基(該アルキル基は、C1-C3アルキルスルホニル基、カルボキシ基及びテトラゾリル基から選択される基で1つ置換されている)、C1-C6アルコキシ基(該アルコキシ基は、C1-C3アルキルスルホニル基、カルボキシ基及びテトラゾリル基から選択される基で1つ置換されている)又はC1-C6アルキルアミノ基(該アルキルアミノ基は、C1-C3アルキルスルホニル基、カルボキシ基及びテトラゾリル基から選択される基で1つ置換されている)を示し、
R9は、C1-C3アルキル基又はC1-C3アルコキシ基を示す]
で表される化合物又はその薬理上許容される塩。
[式中、R1は、水素原子、メチル基又はエチル基を示し、
R2は、フッ素原子又は塩素原子を示し、
R3は、ハロゲン原子を示し、
R5は、カルボキシ基によって1つ置換されたC1-C6アルキル基又はカルボキシ基によって1つ置換されたC1-C6アルコキシ基を示す]
で表される化合物又はその薬理上許容される塩。
前記薬理上許容される塩がナトリウム塩又はカリウム塩である、[1]~[7]のいずれか一項に記載の化合物。
[9]
[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩を有効成分として含有する医薬組成物。
[10]
異所性石灰化の治療又は予防のための[9]に記載の医薬組成物。
[11]
弾性線維性仮性黄色腫(PXE)、乳児全身性動脈石灰化(GACI)、関節と動脈の石灰化(CALJA)、CKD/ESRDにおける血管石灰化、カルシフィラキシス、後縦靱帯骨化症(OPLL)、黄色靭帯骨化症(OYLL)、又は大動脈弁狭窄症の治療又は予防のための[9]に記載の医薬組成物。
[12]
弾性線維性仮性黄色腫(PXE)の治療又は予防のための[9]に記載の医薬組成物。
[13]
[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩を有効成分として含有するTNAP阻害剤。
[14]
対象においてTNAPを阻害するための方法であって、[1]~[7]のいずれか一項に記載の化合物又はその薬理学上許容される塩の有効量を、それを必要とする前記対象に投与することを含む方法。
[15]
異所性石灰化を予防又は治療する方法であって、[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩の薬理的な有効量を、それを必要とする対象に投与することを含む、方法。
[16]
弾性線維性仮性黄色腫(PXE)、乳児全身性動脈石灰化(GACI)、関節と動脈の石灰化(CALJA)、CKD/ESRDにおける血管石灰化、カルシフィラキシス、後縦靱帯骨化症(OPLL)、黄色靭帯骨化症(OYLL)、及び大動脈弁狭窄症からなる群より選ばれる疾病又は病態を予防又は治療する方法であって、[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩の薬理的な有効量を、それを必要とする対象に投与することを含む、方法。
[17]
前記疾病又は病態が、弾性線維性仮性黄色腫(PXE)である、[16]に記載の方法。
[18]
前記対象がヒトである、[14]~[17]のいずれか一項に記載の方法。
[19]
医薬組成物を製造するための、[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩の使用。
[20]
対象においてTNAPを阻害するための、[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩。
[21]
異所性石灰化の治療に用いられる、[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩。
[22]
弾性線維性仮性黄色腫(PXE)、乳児全身性動脈石灰化(GACI)、関節と動脈の石灰化(CALJA)、CKD/ESRDにおける血管石灰化、カルシフィラキシス、後縦靱帯骨化症(OPLL)、黄色靭帯骨化症(OYLL)、及び大動脈弁狭窄症からなる群より選ばれる疾病又は病態の治療に用いられる、[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩。
[23]
弾性線維性仮性黄色腫(PXE)の治療に用いられる、[1]~[7]のいずれか一項に記載の化合物又はその薬理上許容される塩。
一般式(I)のR5が、カルボキシ基で1つ置換されたC1-C6アルキル基、カルボキシ基で1つ置換されたC1-C6ハロアルキル基、又はカルボキシ基で1つ置換されたC1-C6アルコキシ基で示される場合の化合物(Ia)は、例えば、以下の方法により製造することができる。
一般式(I)のR5が、テトラゾリル基で1つ置換された、C1-C6アルキル基、C1-C6ハロアルキル基、又はC1-C6アルコキシ基で示される場合の化合物(Ib)は、例えば、以下の方法により製造することができる。
一般式(I)におけるR5がC1-C6アルキルアミノ基(該アルキルアミノ基は、C1-C3アルキルスルホニル基、カルボキシ基及びテトラゾリル基から選択される基で1つ置換されていてもよい)で示される場合の化合物(Ic)は、例えば、以下の方法により製造することができる。
[製造法3]における化合物の構造式において、R1、R2、R3、R4、R5、X1、及びY2は一般式(I)、[製造法1]、及び[製造法2]と同意義を示す。R8は、C1-C6アルキル基(該アルキル基は、保護されたカルボキシ基及びテトラゾリル基から選択される基で1つ置換されていてもよい)である。L2は、一般的にアミノ基の保護基として使用されるものであり、その例としては、tert-ブトキシカルボニル基が挙げられる。
本発明の一般式(I)を有する化合物又はその薬理上許容される塩は、医薬として使用される場合には、それ自体(原末のまま)で投与することができ、あるいは、適宜の薬剤学的に許容される、錠剤、カプセル剤、顆粒剤、散剤、もしくはシロップ剤等の製剤として経口的に、又は、適宜の薬剤学的に許容される、注射剤、坐剤、もしくは貼付剤等の製剤として非経口的に(好適には、経口的に)投与することができる。
({3’,5’-ジクロロ-2’-[(ピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)酢酸
<1-a> [(2’-アミノ-3’,5’-ジクロロ[1,1’-ビフェニル]-4-イル)オキシ]酢酸メチル(methyl [(2'-amino-3',5'-dichloro[1,1'-biphenyl]-4-yl)oxy]acetate)
窒素雰囲気下、methyl2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]acetate (6.82 g, 23.3mmol)、2-bromo-4,6-dichloro-aniline (7.03 g, 29.2 mmol)、及びpotassium phospate, tribasic (12.4 g, 58.4 mmol)の、1,2-Dimethoxyethane (60 mL)と水 (15 mL)の溶液に、[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complexwith dichloromethane (1.91 g, 2.33 mmol)を加えた。続いて混合物を90℃で3時間加熱攪拌した。室温まで冷却した後に減圧下にて溶媒を留去し、続いて得られた残渣を酢酸エチルと水で希釈した。酢酸エチルで抽出し、あわせた有機層を水、飽和食塩水で順次洗浄して無水硫酸ナトリウムで乾燥した。乾燥剤をろ去し、その後、減圧下にて溶媒を留去して粘性固体を得た。この固体をジクロロメタンに懸濁させて不溶物をセライトろ過にてろ去した。ろ液を減圧下にて溶媒留去して粗生成物を粘性油状物質として得た。この油状物質をシリカゲルカラムクロマトグラフィー[溶出溶媒:ヘキサン/酢酸エチル=89/11-68/32(V/V))]にて精製した。得られた固体をジイソプロピルエーテルでろ取、洗浄し、標記化合物(3.55 g, 10.9 mmol, 47%)を固体として得た。
1H-NMR(CDCl3) δ: 3.84 (3H, s), 4.12 (2H, br s), 4.69 (2H, s), 6.98-7.00(3H, m), 7.24 (1H, d, J = 2.4 Hz), 7.31-7.37 (2H, m).
methyl 2-[4-(2-amino-3,5-dichloro-phenyl)phenoxy]acetate(200 mg, 0.613 mmol)のPyridine (1.5 mL, 19.1 mmol)溶液に、少量のジクロロメタンに溶解したPyridine-3-sulfonyl chloride (109 mg, 0.613 mmol)を加え、混合物を室温で15分間攪拌した後に60℃にて1時間加熱攪拌した。続いて70℃に昇温して反応混合物を1時間加熱攪拌した。Pyridine-3-sulfonyl chloride (111 mg, 0.613 mmol,)を追加した後、90℃に昇温して混合物を同温度で1時間加熱攪拌した。再度Pyridine-3-sulfonyl chloride (232 mg, 1.23 mmol)を追加して同温度で1時間加熱攪拌した。室温まで冷却した後に減圧下にて溶媒を留去して得られた残渣をシリカゲルカラムクロマトグラフィー[溶出溶媒:ヘキサン/酢酸エチル=29/71-8/92(V/V))]にて精製後、さらに逆相シリカゲルカラムクロマトグラフィー[溶出溶媒:水/アセトニトリル=80/20-10/90(V/V))]にて精製し、標記化合物 (57.7 mg, 0.123 mmol, 20.1%)をアモルファスとして得た。
1H-NMR(CDCl3) δ: 3.85 (3H, s), 4.65 (2H, s), 6.41(1H, s), 6.72-6.77 (2H, m), 7.13-7.17 (2H, m), 7.22 (1H, d, J = 2.4 Hz),7.24-7.28 (1H, m), 7.42 (1H, d, J = 2.4 Hz), 7.62-7.67 (1H, m),8.66-8.70 (2H, m).
LCMS (ES): m/z 466.0 [M+H]+.
methyl ({3',5'-dichloro-2'-[(pyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)acetate(56.2 mg, 0.120 mmol)のエタノール (2 mL)溶液に、1mol/L Sodium hydroxide solution (1 mL, 1.0 mmol)を加えて、混合物を室温で1時間攪拌した。減圧下にて溶媒を留去して得た残渣を水で希釈し、1mol/L 塩酸 (1 mL, 1.0 mmol)を加えた。析出した固体をろ取して水、ジイソプロピルエーテルで洗浄した後に減圧下で乾燥することにより、標記化合物 (30.5 mg, 0.0673 mmol, 56%)を固体として得た。
2-({3’,5’-ジクロロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸)(2-({3',5'-dichloro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<2-a> 2-メチル-2-[4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)フェノキシ]プロピオン酸エチル(ethyl2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propanoate)
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol(1.00 g, 4.54 mmol)のAcetonitrile (9 mL)溶液に、Cesium Carbonate (2.37 g, 7.27 mmol)を加え、混合物を攪拌した。続いて2-Bromoisobutyric Acid Ethyl Ester (1.33 g, 6.82 mmol)を加えて9時間加熱還流した。室温まで冷却した後に反応液を酢酸エチルで希釈し、有機層を水、飽和食塩水で順次洗浄して無水硫酸ナトリウムで乾燥した。乾燥剤をろ去した後に減圧下にて溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフィー[溶出溶媒:ヘキサン/酢酸エチル=100/0-80/20(V/V))]にて精製し、標記化合物 (830 mg, 2.48 mmol, 55%)を粘性油状物質として得た。
1H-NMR(CDCl3) δ: 1.22 (3H, t, J = 7.0 Hz), 1.33 (12H, s), 1.62 (6H, s),4.22 (2H, q, J = 7.1 Hz), 6.78-6.82 (2H, m), 7.65-7.72 (2H, m).
実施例(2-a)で得られたethyl 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propanoate(828 mg, 2.48 mmol)と、2-bromo-4,6-dichloro-aniline (748mg, 3.10 mmol)を用い、実施例(1-a)と同様にして、標記化合物 (794 mg, 2.16mmol, 87%)を油状物質として得た。
1H-NMR(CDCl3) δ: 1.27 (3H, t, J = 7.3 Hz), 1.64 (6H, s), 4.12 (2H, br s),4.27 (2H, q, J = 7.1 Hz), 6.89-6.94 (2H, m), 6.99 (1H, d, J = 2.4 Hz),7.23-7.30 (3H, m).
LCMS (ES): m/z 368 [M+H]+.
実施例(2-b)で得られたethyl2-[(2'-amino-3',5'-dichloro[1,1'-biphenyl]-4-yl)oxy]-2-methylpropanoate (207mg, 0.562 mmol)と、5-methylpyridine-3-sulfonyl chloride(253 mg, 1.32 mmol)を用い、実施例(1-b)と同様にして、標記化合物 (52.7 mg,0.101 mmol, 18%)を固体として得た。
LCMS (ES): m/z 368 [M+H]+.
実施例(2-c)で得られたethyl2-({3',5'-dichloro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoate(52.5 mg, 0.100 mmol)を用い、実施例(1-c)と同様にして、標記化合物 (38.9 mg,0.0785 mmol, 78%) を固体として得た。
2-({5’-クロロ-3’-フルオロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<3-a> 2-[(2’-アミノ-5’-クロロ-3’-フルオロ[1,1’-ビフェニル]-4-イル)オキシ]-2-メチルプロピオン酸エチル(ethyl2-[(2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-methylpropanoate)
実施例(2-a)で得られたethyl2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propanoate (522 mg, 1.57 mmol)と、2-bromo-4-chloro-6-fluoro-aniline(321 mg, 1.43 mmol)を用い、実施例(1-a)と同様にして、標記化合物 (467 mg,1.33 mmol, 93%)を固体として得た。
1H-NMR(CDCl3) δ: 1.27 (3H, t, J = 7.0 Hz), 1.64 (6H, s), 3.78 (2H, br s),4.27 (2H, q, J = 7.1 Hz), 6.89-6.94 (3H, m), 6.99 (1H, dd, J = 10.3, 2.4 Hz),7.28-7.32 (2H, m).
LCMS (ES): m/z 352 [M+H]+.
実施例(3-a)で得られたethyl2-[(2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-methylpropanoate(151 mg, 0.429 mmol)と、5-methylpyridine-3-sulfonylchloride (98.2 mg, 0.512 mmol)を用い、実施例(1-b)と同様にして、標記化合物(72.6 mg, 0.101 mmol, 33%)を粘性油状物質として得た。
1H-NMR(CDCl3) δ: 1.28 (3H, t, J = 7.0 Hz), 1.64 (6H, s), 2.36 (3H, s),4.26 (2H, q, J = 7.1 Hz), 6.22 (1H, br s), 6.77-6.82 (2H, m), 7.06-7.14 (4H,m), 7.63-7.65 (1H, br m), 8.56 (1H, d, J = 1.2 Hz), 8.63 (1H, d, J = 1.8 Hz).
LC-MS (ES): m/z 507 [M+H]+.
実施例(3-b)で得られたethyl 2-({5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoate(71.1 mg, 0.140 mmol)を用い、実施例(1-c)と同様にして、標記化合物 (62.8 mg,0.131 mmol, 93%) を固体として得た。
3-({5’-クロロ-3’-フルオロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}プロピオン酸(3-{5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}propanoicacid)
<4-a> 3-(2’-アミノ-5’-クロロ-3’-フルオロ[1,1’-ビフェニル]-4-イル)プロピオン酸エチル(ethyl 3-(2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)propanoate)
2-bromo-4-chloro-6-fluoroaniline (620 mg,2.76 mmol)と、[4-(2-ethoxycarbonylethyl)phenyl]boronicacid (680 mg, 3.04 mmol)を用い、実施例(1-a)と同様にして、標記化合物(690mg, 2.14 mmol, 77.6%)を油状物質として得た。
LCMS (ES): m/z 322 [M+H]+ .
実施例(4-a)で得られたethyl3-(2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)propanoate(170 mg, 0.528mmol)と、5-methylpyridine-3-sulfonyl chloride (101 mg,0.528 mmol)を用い、実施例(1-b)と同様にして、標記化合物(105 mg, 0.220 mmol,41.7%)を油状物質として得た。
1H-NMR(CDCl3) δ: 1.27 (3H, t, J = 7.1 Hz), 2.34 (3H, s), 2.65 (2H, t, J =7.6 Hz), 2.97 (2H, t, J = 7.8 Hz), 4.17 (2H, q, J = 7.0 Hz), 6.35 (1H, s), 7.10(1H, dd, J = 2.4, 1.5 Hz), 7.17-7.13 (3H, m), 7.19 (2H, d, J = 7.8 Hz), 7.65(1H, s), 8.54 (1H, d, J = 1.5 Hz), 8.60 (1H, d, J = 2.0 Hz).
LCMS (ES): m/z 477 [M+H]+ .
実施例(4-b)で得られたethyl3-{5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}propanoate(105 mg, 0.220 mmol)を用い、実施例(1-c)と同様にして、標記化合物(90 mg,0.200 mmol, 91.1%)を固体として得た。
N-{5’-クロロ-3’-フルオロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}グリシン(N-{5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}glycine)
<5-a> エチル N-(tert-ブトキシカルボニル)-N-[4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)フェニル]グリシン酸
ethylN-(tert-butoxycarbonyl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]glycinate
t-ButylN-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate (1.0 g, 3.1 mmol)のN,N-Dimethylformamide (10 mL)溶液に、CesiumCarbonate (2.1 g, 6.3 mmol)、Ethyl iodoacetate (0.45 ml,3.8 mmol)を加えて、混合物を室温で16時間攪拌した。反応液を濃縮し、得られた残渣にジクロロメタンを加え、析出した固体をろ別した。母液を再度濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー[溶出溶媒:ヘキサン/酢酸エチル=100/0-70/30(V/V))]にて精製し、標記化合物 (2.14 g, 3.26 mmol, 66%) を油状物質として得た。
1H-NMR(CDCl3) δ: 1.28 (3H, t, J = 7.1 Hz), 1.34 (12H, s), 1.44 (9H, s),4.22 (2H, q, J = 7.1 Hz), 4.30 (2H, s), 7.27-7.31 (2H, m), 7.77 (2H, d, J = 8.3Hz).
LCMS (ES): m/z 306 [M+H-BOC]+ .
実施例(5-a)で得られたethylN-(tert-butoxycarbonyl)-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]glycinate(1.15 g, 2.51 mmol)と、2-bromo-4-chloro-6-fluoroaniline(470 mg, 2.09 mmol)を用い、実施例(1-a)と同様にして、標記化合物(665 mg,1.57 mmol, 75.1%)を油状物質として得た。
1H-NMR(CDCl3) δ: 1.33 (3H, t, J = 7.1 Hz), 1.50 (9H, s), 3.83 (2H, s),4.27 (2H, q, J = 7.2 Hz), 4.33 (2H, s), 6.93 (1H, s), 7.03 (1H, dd, J = 10.3,2.4 Hz), 7.36-7.48 (4H, m).
LCMS (ES): m/z 323 [M+H-BOC]+ .
実施例(5-b)で得られたethylN-(2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)-N-(tert-butoxycarbonyl)glycinate(175mg, 0.414 mmol)を用い、実施例(1-b)と同様にして、標記化合物(91 mg, 0.157mmol, 38%)を油状物質として得た。
1H-NMR(CDCl3) δ: 1.34 (3H, t, J = 7.1 Hz), 1.49 (9H, s), 2.37 (3H, s),4.28 (2H, q, J = 7.0 Hz), 4.34 (2H, s), 6.28 (1H, s), 7.11 (1H, s), 7.14 (1H,dd, J = 9.3, 2.4 Hz), 7.21 (2H, d, J = 8.8 Hz), 7.32 (2H, d, J = 8.3 Hz), 7.72(1H, s), 8.55 (1H, s), 8.59 (1H, d, J = 2.0 Hz).
LCMS (ES): m/z 578 [M+H]+ .
実施例(5-c)で得られたethyl N-(tert-butoxycarbonyl)-N-{5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}glycinate(91 mg, 0.157 mmol)をジクロロメタン(5 mL)に溶解した。溶液に室温でtrifluoroacetic acid (2 mL)を加え、混合物を12時間攪拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え、ジクロロメタン、酢酸エチルで抽出した。有機層を濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー[溶出溶媒:ヘキサン/酢酸エチル=70/30-0/100(V/V))]にて精製し、標記化合物 (48 mg, 0.075 mmol, 64%) を油状物質として得た。
1H-NMR(CDCl3) δ: 1.34 (3H, t, J = 7.1 Hz), 2.32 (3H, s), 3.91 (2H, s),4.29 (2H, q, J = 7.2 Hz), 6.31-6.38 (1H, m), 6.52 (2H, dd, J = 6.3, 2.0 Hz),7.03 (2H, dd, J = 6.3, 2.0 Hz), 7.11-7.06 (2H, m), 7.62 (1H, s), 8.52 (1H, s),8.62 (1H, s).
LCMS (ES): m/z 478 [M+H]+ .
実施例(5-d)で得られたethylN-{5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}glycinate(48 mg, 0.10 mmol)を用い、実施例(1-c)と同様にして、標記化合物(28 mg, 0.062mmol, 62%)を固体として得た。
N-{5-クロロ-3-フルオロ-4’-[(2H-テトラゾール-5-イル)メトキシ][1,1’-ビフェニル]-2-イル}-5-メチルピリジン-3-スルホンアミド(N-{5-chloro-3-fluoro-4'-[(2H-tetrazol-5-yl)methoxy][1,1'-biphenyl]-2-yl}-5-methylpyridine-3-sulfonamide)
<6-a> 2-(オキサン-2-イル)-5-{[4-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)フェノキシ]メチル}-2H-テトラゾール(2-(oxan-2-yl)-5-{[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl}-2H-tetrazole)
5-Chloromethyl-1H-tetrazole (1.1 g, 8.44mmol)をacetone (20 mL)に溶解した。溶液に3,4-Dihydro-2H-pyran(1.2 ml, 12.7 mmol)とPyridinium p-Toluenesulfonate (52mg, 0.169 mmol)を加え、混合物を50度で7時間攪拌した。反応液に4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol(1.3 g, 5.91 mmol)、Cesium carbonate (6.6 g, 21.1 mmol)を加え、混合物を60度で3時間攪拌した。反応液中の不溶物をろ別し、母液を濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー[溶出溶媒:ヘキサン/酢酸エチル=100/0-70/30(V/V))]にて精製し、標記化合物 (2.14 g, 3.26 mmol, 66%) を油状物質として得た。
1H-NMR(CDCl3) δ: 1.33 (12H, s), 1.69-1.82 (3H, m), 2.10-2.21 (2H, m),2.37-2.49 (1H, m), 3.84-3.76 (1H, m), 4.02-3.95 (1H, m), 5.37 (2H, s),6.01-6.05 (1H, m), 7.03 (2H, d, J = 8.6 Hz), 7.76 (2H, d, J = 8.6 Hz).
LCMS (ES): m/z 303 [M+H-THP]+.
実施例(6-a)で得られた2-(oxan-2-yl)-5-{[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl}-2H-tetrazole(2.14 g, 5.54 mmol)を用い、実施例(1-a)と同様にして、標記化合物(790 mg,1.96 mmol, 35.3%)を油状物質として得た。
1H-NMR(CDCl3) δ: 1.72-1.82 (3H, m), 2.22-2.11 (2H, m), 2.41-2.50 (1H, m),3.75-3.84 (3H, m), 4.00-4.03 (1H, m), 5.40 (2H, s), 6.06 (1H, dd, J = 7.8, 2.9Hz), 6.91 (1H, t, J = 1.7 Hz), 7.00 (1H, dd, J = 10.3, 2.4 Hz), 7.13 (2H, dt, J= 9.3, 2.6 Hz), 7.37 (2H, dt, J = 9.3, 2.6 Hz).
及び
N-(5-クロロ-3-フルオロ-4’-{[2-(オキサン-2-イル)-2H-テトラゾール-5-イル]メトキシ}[1,1’-ビフェニル]-2-イル)-5-メチル-N-(5-メチルピリジン-3-スルホニル)ピリジン-3-スルホンアミド(N-(5-chloro-3-fluoro-4'-{[2-(oxan-2-yl)-2H-tetrazol-5-yl]methoxy}[1,1'-biphenyl]-2-yl)-5-methyl-N-(5-methylpyridine-3-sulfonyl)pyridine-3-sulfonamide)
実施例(6-b)で得られた5-chloro-3-fluoro-4'-{[2-(oxan-2-yl)-2H-tetrazol-5-yl]methoxy}[1,1'-biphenyl]-2-amine(460mg, 1.14 mmol)を用い、実施例(1-b)と同様にして、2つの標記化合物の混合物(584 mg)を油状物質として得た。
LCMS (ES): m/z 559 [M+H]+ , 715[M+H]+.
実施例(6-c)で得られたN-(5-chloro-3-fluoro-4'-{[2-(oxan-2-yl)-2H-tetrazol-5-yl]methoxy}[1,1'-biphenyl]-2-yl)-5-methylpyridine-3-sulfonamideとN-(5-chloro-3-fluoro-4'-{[2-(oxan-2-yl)-2H-tetrazol-5-yl]methoxy}[1,1'-biphenyl]-2-yl)-5-methyl-N-(5-methylpyridine-3-sulfonyl)pyridine-3-sulfonamideの混合物(584 mg)を、メタノール(5 mL)とテトラヒドロフラン(5 mL)の混合溶媒に溶解した。溶液に1 mol/L 水酸化ナトリウム溶液(2.0 ml, 2.0 mmol)を加え、室温で4時間攪拌した。反応液に、1mol/L Hydrochloric acid (4.0 ml, 4.0 mmol)を加えて、混合物を50度で2時間攪拌した。反応液に1mol/L 水酸化ナトリウム溶液(2.0 ml, 2.0 mmol)を加えて中和した後、ジクロロメタン、酢酸エチルで抽出した。有機層を減圧下濃縮し、得られた残渣を逆相シリカゲルカラムクロマトグラフィー[溶出溶媒:水/アセトニトリル=80/20-10/90(V/V))]にて精製し、標記化合物 (270 mg, 0.569 mmol, 50.0% for 2 steps) を固体として得た。
2-({5’-クロロ-2’-[(5-エチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({5'-chloro-2'-[(5-ethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<7-a> 2-({5’-クロロ-2’-[(5-エチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸エチル(ethyl 2-({5'-chloro-2'-[(5-ethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoate)
実施例(3-a)で得られたethyl2-[(2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-methylpropanoate (130mg, 0.370 mmol)と、5-ethylpyridine-3-sulfonyl chloride(120 mg, 0.480 mmol)を用い、実施例(1-b)と同様にして、標記化合物(100 mg,0.192 mmol, 51.9%)を固体として得た。
1H-NMR(CDCl3) δ: 1.26 (3H, t, J = 7.8 Hz), 1.28 (3H, t, J = 6.8 Hz), 1.64(6H, s), 2.70 (2H, q, J = 7.6 Hz), 4.27 (2H, q, J = 7.2 Hz), 6.21 (1H, s), 6.82(2H, d, J = 8.8 Hz), 7.12-7.08 (2H, m), 7.13 (2H, d, J = 8.8 Hz), 7.72 (1H, s),8.59 (1H, d, J = 2.0 Hz), 8.66 (1H, d, J = 2.4 Hz).
LCMS (ES): m/z 521 [M+H]+.
実施例(7-a)で得られたethyl2-({5'-chloro-2'-[(5-ethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoate(100 mg, 0.191 mmol)を用い、実施例(1-c)と同様にして、標記化合物(55 mg,0.112 mmol, 58.1%)を固体として得た。
2-({5’-クロロ-2’-[(4,5-ジメチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<8-a> 2-({5’-クロロ-2’-[(4,5-ジメチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸エチル(ethyl 2-({5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoate)
実施例(3-a)で得られたethyl2-[(2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)oxy]-2-methylpropanoate(11.7g, 33.3 mmol)をピリジン(12 mL)に溶解し、反応液を70度に加熱した。その後、4,5-dimethylpyridine-3-sulfonylchloride (10.3 g, 50.0 mmol)のジクロロメタン(100 mL)溶液を1時間かけて滴下した。混合物を70度で2時間攪拌した。反応液に水を加え、ジクロロメタンで抽出した。抽出液をシリカゲルカラムクロマトグラフィー[溶出溶媒:ヘキサン/酢酸エチル=80/20-50/50(V/V))]にて精製し、標記化合物 (5.33 g, 10.2 mmol, 30.7%) を固体として得た。
1H-NMR(CDCl3) δ: 1.28 (3H, q, J = 6.5 Hz), 1.63 (6H, s), 2.27 (3H, s),2.36 (3H, s), 4.26 (2H, q, J = 7.0 Hz), 6.22 (1H, s), 6.75 (2H, d, J = 8.8 Hz),7.06-7.01 (3H, m), 7.11 (1H, dd, J = 9.3, 2.4 Hz), 8.44 (1H, s), 8.67 (1H, s).
LCMS (ES): m/z 521 [M+H]+.
実施例(8-a)で得られたethyl2-({5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoate(156mg, 0.299 mmol)を用い、実施例(1-c)と同様にして、標記化合物(132 mg, 0.268mmol, 89.4%)を固体として得た。
2-({5’-クロロ-2’-[(4,5-ジメチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸 カリウム塩(potassium2-({5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoate)
実施例8で得られた2-({5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid(101 mg, 0.205 mmol)をエタノール(2 mL)に溶解した。溶液に0.5mol/lのPotassium hydroxide ethanolsolution (0.410 ml, 0.205 mmol)を加え、混合物を室温で20分間攪拌した。反応液を濃縮し、得られた残渣にジエチルエーテルを加えた。析出した固体をろ取した後、50度で減圧乾燥を行い、標記化合物(90.0 mg, 0.169 mmol, 82.7%)を固体として得た。
2-({5’-クロロ-2’-[(4,5-ジメチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸 ナトリウム塩(sodium2-({5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoate)
実施例8で得られた2-({5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid(101 mg, 0.205 mmol)をエタノール(2 mL)に溶解した。溶液に2mol/L水酸化ナトリウム溶液 (0.103 ml, 0.205 mmol)を加え、混合物を室温で20分間攪拌した。反応液を濃縮し、得られた残渣にジエチルエーテルを加えた。析出した固体をろ取した後、50度で減圧乾燥を行い、標記化合物(92.0 mg, 0.179 mmol, 87.2%)を固体として得た。
{5’-クロロ-3’-フルオロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}酢酸({5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}aceticacid)
<11-a> (2’-アミノ-5’-クロロ-3’-フルオロ[1,1’-ビフェニル]-4-イル)酢酸エチル(ethyl (2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)acetate)
2-bromo-4-chloro-6-fluoroaniline (1.00 g,4.46 mmol, 1.0g)とethyl2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate (1.56 g, 5.35mmol)を用い、実施例(1-a)と同様にして、標記化合物(1.15 g, 3.74 mmol, 83.9%)を油状物質として得た。
1H-NMR(CDCl3) δ: 1.29 (3H, t, J = 7.3 Hz), 3.66 (2H, s), 4.19 (2H, q, J =7.2 Hz), 6.92 (1H, dd, J = 2.4, 1.5 Hz), 7.01 (1H, dd, J = 10.7, 2.4 Hz), 7.39(4H, s).
実施例(11-a)で得られたethyl(2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)acetate (240 mg, 0.780 mmol)と、5-methylpyridine-3-sulfonyl chloride;hydrochloride (180 mg, 0.936mmol)を用い、実施例(1-b)と同様にして、標記化合物(153 mg, 0.331 mmol, 42.4%)を油状物質として得た。
1H-NMR(CDCl3) δ: 1.29 (3H, t, J = 7.1 Hz), 2.33 (3H, s), 3.64 (2H, s),4.19 (2H, q, J = 7.2 Hz), 6.34 (1H, br s), 7.11-7.15 (2H, m), 7.20 (2H, dt, J =8.3, 1.7 Hz), 7.28 (2H, d, J = 7.8 Hz), 7.66 (1H, s), 8.54 (1H, s), 8.61 (1H,d, J = 1.5 Hz).
LCMS (ES): m/z 463 [M+H]+.
実施例(11-b)で得られたethyl{5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}acetate(144mg, 0.311 mmol)を用い、実施例(1-c)と同様にして、標記化合物(118 mg, 0.271mmol, 87.2%)を固体として得た。
{5’-クロロ-2’-[(4,5-ジメチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}酢酸({5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}aceticacid)
<12-a> {5’-クロロ-2’-[(4,5-ジメチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}酢酸エチル(ethyl{5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}acetate)
実施例(11-a)で得られたethyl (2'-amino-5'-chloro-3'-fluoro[1,1'-biphenyl]-4-yl)acetate(160mg, 33.3 mmol)を用い、実施例(1-b)と同様にして、標記化合物(170mg, 0.356mmol, 68.6%)を固体として得た。
1H-NMR(CDCl3) δ: 1.29 (3H, t, J = 7.3 Hz), 2.23 (3H, s), 2.35 (3H, s),3.62 (2H, s), 4.19 (2H, q, J = 7.2 Hz), 6.31 (1H, br s), 7.05 (1H, t, J = 1.7Hz), 7.11-7.15 (3H, m), 7.23 (2H, d, J = 8.3 Hz), 8.42 (1H, s), 8.66 (1H, s).
LCMS (ES): m/z 477 [M+H]+.
実施例(12-a)で得られたethyl{5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}acetate(170mg, 0.356 mmol)を用い、実施例(1-c)と同様にして、標記化合物(120 mg, 0.267mmol, 75.0%)を固体として得た。
<実施例13>
2-({3’,5’-ジクロロ-2’-[(ピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)プロピオン酸(2-({3',5'-dichloro-2'-[(pyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)propanoicacid)
<実施例14>
2-({3’,5’-ジクロロ-2’-[(ピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({3',5'-dichloro-2'-[(pyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<実施例15>
({3’,5’-ジクロロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)酢酸(({3',5'-dichloro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)aceticacid)
<実施例16>
({5’-クロロ-3’-フルオロ-2’-[(ピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)酢酸(({5'-chloro-3'-fluoro-2'-[(pyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)aceticacid)
<実施例17>
({5’-クロロ-3’-フルオロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)酢酸(({5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)aceticacid)
<実施例18>
2-({5’-クロロ-3’-フルオロ-2’-[(5-メトキシピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({5'-chloro-3'-fluoro-2'-[(5-methoxypyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<実施例19>
2-({3’,5’-ジクロロ-2’-[(5-メトキシピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)プロピオン酸(2-({3',5'-dichloro-2'-[(5-methoxypyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)propanoicacid)
<実施例20>
{3’,5’-ジクロロ-2’-[(5-メトキシピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}(ジフルオロ)酢酸({3',5'-dichloro-2'-[(5-methoxypyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}(difluoro)aceticacid)
<実施例21>
N-[3,5-ジクロロ-3’-フルオロ-4’-(メタンスルホニル)[1,1’-ビフェニル]-2-イル]-5-メトキシピリジン-3-スルホンアミド(N-[3,5-dichloro-3'-fluoro-4'-(methanesulfonyl)[1,1'-biphenyl]-2-yl]-5-methoxypyridine-3-sulfonamide)
<実施例22>
{3’,5’-ジクロロ-2’-[(5-メトキシピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}酢酸({3',5'-dichloro-2'-[(5-methoxypyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}aceticacid)
<実施例23>
2-({5’-クロロ-3’-フルオロ-2’-[(4-メチルピリミジン-5-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({5'-chloro-3'-fluoro-2'-[(4-methylpyrimidine-5-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<実施例24>
2-({5’-クロロ-2’-[(4-エチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({5'-chloro-2'-[(4-ethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<実施例25>
2-({5’-クロロ-3’-フルオロ-2’-[(4-メトキシピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({5'-chloro-3'-fluoro-2'-[(4-methoxypyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<実施例26>
2-{[5’-クロロ-3’-フルオロ-2’-({5-[(プロパン-2-イル)オキシ]ピリジン-3-スルホニル}アミノ)[1,1’-ビフェニル]-4-イル]オキシ}-2-メチルプロピオン酸(2-{[5'-chloro-3'-fluoro-2'-({5-[(propan-2-yl)oxy]pyridine-3-sulfonyl}amino)[1,1'-biphenyl]-4-yl]oxy}-2-methylpropanoicacid)
<実施例27>
2-({5’-クロロ-3,3’-ジフルオロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}オキシ)-2-メチルプロピオン酸(2-({5'-chloro-3,3'-difluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}oxy)-2-methylpropanoicacid)
<実施例28>
2-[(5’-クロロ-3’-フルオロ-2’-{[5-(メタンスルホニル)ピリジン-3-スルホニル]アミノ}[1,1’-ビフェニル]-4-イル)オキシ]-2-メチルプロピオン酸(2-[(5'-chloro-3'-fluoro-2'-{[5-(methanesulfonyl)pyridine-3-sulfonyl]amino}[1,1'-biphenyl]-4-yl)oxy]-2-methylpropanoicacid)
<実施例29>
3-({5’-クロロ-2’-[(5-エチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}プロピオン酸(3-{5'-chloro-2'-[(5-ethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}propanoicacid)
<実施例30>
3-[5’-クロロ-3’-フルオロ-2’-({5-[(プロパン-2-イル)オキシ]ピリジン-3-スルホニル}アミノ)[1,1’-ビフェニル]-4-イル]プロピオン酸(3-[5'-chloro-3'-fluoro-2'-({5-[(propan-2-yl)oxy]pyridine-3-sulfonyl}amino)[1,1'-biphenyl]-4-yl]propanoicacid)
<実施例31>
3-({5’-クロロ-2’-[(4,5-ジメチルピリジン-3-スルホニル)アミノ]-3’-フルオロ[1,1’-ビフェニル]-4-イル}プロピオン酸(3-{5'-chloro-2'-[(4,5-dimethylpyridine-3-sulfonyl)amino]-3'-fluoro[1,1'-biphenyl]-4-yl}propanoicacid)
<実施例32>
2-{5’-クロロ-3’-フルオロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}プロピオン酸(2-{5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}propanoicacid)
<実施例33>
2-{5’-クロロ-3’-フルオロ-2’-[(5-メチルピリジン-3-スルホニル)アミノ][1,1’-ビフェニル]-4-イル}ブタン酸(2-{5'-chloro-3'-fluoro-2'-[(5-methylpyridine-3-sulfonyl)amino][1,1'-biphenyl]-4-yl}butanoicacid)
(試験例1)TNAP活性阻害試験
ヒトTNAP(オリジンテクノロジーズ社)をLipofectamine LTX & Plus reagent (インビトロジェン社)にてCOS1細胞(DSファーマバイオケミカル株式会社)にトランスフェクションした。翌日、培地交換を行い、細胞をインキュベーター内で3日間培養した。3日後培養上清を回収し、Amicon 14, 104cut(Merck Millipore)で5000G、30分間の遠心を行い培養上清を濃縮した。濃縮した培養上清は5Lの50mM Tris/200mM NaCl/1mM MgCl2/20μM ZuCl2で2回透析し、それを酵素源(酵素溶液)として用いた。基質であるpNPP(プロテオケム社)をミリQ水で3.1mMに調整し、試験化合物をジメチルスルホキシド(DMSO、和光純薬工業社)に100μMから5倍公比、6段階の希釈になるよう溶解した溶液、又はDMSOを、最終濃度1容量%になるように添加した。アッセイバッファー(200mMTris/2mM MgCl2/0.04mM ZnCl2/0.01% Tween20)で2μg/mLに調整した酵素溶液を、基質液と同量加え、室温で60分間インキュベーションした。その後、マイクロプレートリーダー(model plus 384,Molecular device, LLC)にて吸光度(ABS:405 nm)を測定し、生成したパラニトロフェノール濃度を算出した。試験化合物のヒトTNAP活性阻害は、パラニトロフェノールの生成を50%抑制する各試験化合物の濃度であるIC50値により評価した。
結果を表2に示す。
ヒトIAP(小腸型アルカリホスファターゼ、オリジンテクノロジーズ社より購入)、又はヒトPLAP(胎盤型アルカリホスファターゼ、オリジンテクノロジーズ社より購入)を、LipofectamineLTX & Plus reagent(インビトロジェン社)にてCOS1細胞(DSファーマバイオケミカル株式会社)にトランスフェクションした。翌日、培地交換を行い、細胞を3日間インキュベーター内で培養した。3日後、培養上清を回収しAmicon14, 104cut(Merck Millipore)で5000G、30分間の遠心を行い培養上清を濃縮した。濃縮した培養上清を5Lの50mM Tris/200mM NaCl/1mM MgCl2/20μM ZuCl2で2回透析し、それを酵素源(酵素溶液)として用いた。基質であるpNPP(プロテオケム社)をミリQ水で3.1mMに調整し、試験化合物をジメチルスルホキシド(DMSO、和光純薬工業社)に100μMから5倍公比、6段階の希釈になるよう溶解した溶液、又はDMSOを、最終濃度1容量%になるように添加した。ヒトIAP又はヒトPLAPの酵素溶液をアッセイバッファー(200mM Tris/2mM MgCl2/0.04mMZnCl2/0.01% Tween20)で2μg/mLに調整し、基質液と同量加え、室温で60分間インキュベーションした。その後、マイクロプレートリーダー(model plus384, Molecular device)にて吸光度(ABS:405 nm)を測定し、生成したパラニトロフェノール濃度を算出した。試験化合物のヒトIAP又はPLAP活性阻害は、パラニトロフェノールの生成を50%抑制する各試験化合物の濃度であるIC50値により評価した。
ヘパリン処理したヘマトクリット毛細管(EMマイスターヘマトクリット毛細管、アズワン(株))にて尾静脈採血(化合物投与前サンプル)の後、0.5%メチルセルロース液(和光純薬工業(株)より購入した粉末を大塚蒸留水で0.5%に調整)に懸濁した試験化合物(0.3 mg/kg)をマウスに経口投与した。投与後1、2、4、6、および24時間後にヘパリン処理したヘマトクリット毛細管にて尾静脈を採血し、血漿サンプルを得た。アッセイバッファー(1M Tris, 1M MgCl2, 20mM ZnCl2, water, pH7.5)に血漿サンプルを添加し、今後物を5分静置した。その後、405 nmの吸光度を測定しblank値とした。基質であるpNPPを添加し室温で180分間インキュベーションした。その後、マイクロプレートリーダー(model plus 384、Molecular device)にて吸光度を測定し(ABS:405nm)、生成したパラニトロフェノール濃度を算出した。測定値はblank値を差し引き、化合物投与前サンプルのTNAP活性を100%として各時点におけるTNAP活性を算出した。
100-((0時間での血漿ALP活性 + 1時間での血漿ALP活性)*1/2+ (1時間での血漿ALP活性 + 2時間での血漿ALP活性)*1/2 + (2時間での血漿ALP活性 + 4時間での血漿ALP活性)*2/2 + (4時間での血漿ALP活性 + 6時間での血漿ALP活性)*2/2)/6
結果を表3に示す。
DBA/2マウス(雄性、使用時6週齢、日本チャールス・リバー(株))に試験化合物を含む粉末飼料(FR-2粉末飼料、株式会社船橋農場)を与える。翌日より3日間、3.75mg/kgのコレカルシフェロール(シグマアルドリッチ社)を腹腔内投与する。コレカルシフェロール投与終了7日後に動物を安楽殺し、胸大動脈、腎臓を採材する。組織を凍結乾燥後(FREEZE DRYER, FRD-50M、IWAKI ASAHI TECHNO GLASS社)、各組織に10%ギ酸(キシダ化学株式会社より購入した原液をミリQ水にて10%に調整)を添加して、QIAGEN Retsch MM300 TissueLyser(QIAGEN)で破砕する。破砕液は遠心し、上清をサンプルとする。サンプル中のカルシウム濃度はCalcium assay kit(和光純薬工業社)を用いて吸光度(ABS 612nm, Microplate reader, model plus 384, Molecular device)にて測定し、組織中カルシウム量を算出する。
クレア株式会社より、5/6腎摘手術を実施したDBA/2マウス(雄性、8週齢)を購入する。当マウスに1.2%高リン食(オリエンタル酵母(株))を負荷する。0.5%メチルセルロース溶液(和光純薬工業(株)より購入した粉末を大塚蒸留水で0.5%に調整)に懸濁した各試験化合物をマウスに経口投与する。化合物投与3ヶ月後に動物を安楽殺し、腎臓を採材する。組織は凍結乾燥後(FREEZE DRYER, FRD-50M, IWAKI ASAHI TECHNO GLASS)、10%ギ酸(キシダ化学株式会社より購入した原液をミリQ水にて10%に調整)を添加してQIAGEN Retsch MM300 TissueLyser(株式会社キアゲン)で破砕する。破砕液は遠心し、上清をサンプルとする。サンプル中のカルシウム濃度はCalcium assay kit(和光純薬工業社)を用いて吸光度(ABS 612nm, Microplate reader, model plus 384, Molecular device)にて測定し、組織中カルシウム量を算出する。
薬物動態試験は、薬物動力学の分野において周知の方法にしたがって行うことができる。
各試験化合物を0.5%メチルセルロース水溶液に懸濁した。得られた懸濁液を一般に薬物動態試験に使用される動物(例えば、マウス、ラット、イヌ、又はカニクイサル)に対し、適当な範囲の用量(例えば、0.01 mg/kgから10 mg/kg)で経口投与した。また、試験化合物を生理食塩水に溶解した。得られた溶液を一般に薬物動態試験に使用される動物(例えば、マウス、ラット、イヌ、カニクイサル)に対し、適当な範囲の用量(例えば、0.1 mg/kgから10 mg/kg)で静脈(例えば、尾静脈、橈側皮静脈、又は伏在静脈)の内に投与した。投与から一定時間(例えば、0.08、0.25、0.5、1、2、4、6、8、および、24時間)の後に、適当な採血部位(例えば、頚静脈、橈側皮静脈、又は伏在静脈等)より血液を採取した。得られた血液を遠心分離して血漿試料を調製した。液体クロマトグラフィー質量分析計(LC-MS/MS)を用いた定量分析により、血漿試料中に含まれる試験化合物の濃度を測定した。
試験化合物の薬物動態は、最高血漿中濃度(Cmax)、血漿中濃度-時間曲線下面積(AUC)、全身クリアランス(CL)、及び、バイオアベイラビリティにより評価し、解析にはソフトウェア(Phoenix等)を用いた。Cmaxは、試験化合物を経口投与後の最高血漿中濃度を示す。AUCは、試験化合物を投与した時点から定量可能であった最終時点までの血漿中濃度から台形公式により算出した。バイオアベイラビリティは、下記式
[(経口投与後のAUC/経口投与の投与量)/(静脈内投与後のAUC/静脈内投与の投与量)]
により算出した。
<製剤例>
(製剤例1)カプセル剤
実施例31の化合物 50mg
乳糖 128mg
トウモロコシデンプン 70mg
ステアリン酸マグネシウム 2mg
-----------------
250mg
上記処方の粉末を混合し、60メッシュのふるいを通した後、この粉末をゼラチンカプセルに入れ、カプセル剤とする。
(製剤例2)錠剤
実施例31の化合物 50mg
乳糖 126mg
トウモロコシデンプン 23mg
ステアリン酸マグネシウム 1mg
-----------------
200mg
上記処方の粉末を混合し、トウモロコシデンプン糊を用いて造粒、乾燥した後、打錠機により打錠して、錠剤(各200mg)を調製する。この錠剤は必要に応じてコーティングを施すことができる。
Claims (16)
- 前記薬理上許容される塩がナトリウム塩又はカリウム塩である、請求項1~5のいずれか一項に記載の化合物。
- 請求項1~5のいずれか一項に記載の化合物又はその薬理上許容される塩を有効成分として含有する医薬組成物。
- 異所性石灰化の治療又は予防のための請求項7に記載の医薬組成物。
- 弾性線維性仮性黄色腫(PXE)、乳児全身性動脈石灰化(GACI)、関節と動脈の石灰化(CALJA)、CKD/ESRDにおける血管石灰化、カルシフィラキシス、後縦靱帯骨化症(OPLL)、黄色靭帯骨化症(OYLL)、又は大動脈弁狭窄症の治療又は予防のための請求項7に記載の医薬組成物。
- 弾性線維性仮性黄色腫(PXE)の治療又は予防のための請求項7に記載の医薬組成物。
- 請求項1~5のいずれか一項に記載の化合物又はその薬理上許容される塩を有効成分として含有するTNAP阻害剤。
- 医薬組成物を製造するための、請求項1~5のいずれか一項に記載の化合物又はその薬理上許容される塩の使用。
- 対象においてTNAPを阻害するための、請求項1~5のいずれか一項に記載の化合物又はその薬理上許容される塩。
- 異所性石灰化の治療又は予防に用いられる、請求項1~5のいずれか一項に記載の化合物又はその薬理上許容される塩。
- 弾性線維性仮性黄色腫(PXE)、乳児全身性動脈石灰化(GACI)、関節と動脈の石灰化(CALJA)、CKD/ESRDにおける血管石灰化、カルシフィラキシス、後縦靱帯骨化症(OPLL)、黄色靭帯骨化症(OYLL)、及び大動脈弁狭窄症からなる群より選ばれる疾病又は病態の治療又は予防に用いられる、請求項1~5のいずれか一項に記載の化合物又はその薬理上許容される塩。
- 弾性線維性仮性黄色腫(PXE)の治療又は予防に用いられる、請求項1~5のいずれか一項に記載の化合物又はその薬理上許容される塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862749590P | 2018-10-23 | 2018-10-23 | |
US62/749,590 | 2018-10-23 | ||
PCT/US2019/057314 WO2020086504A1 (en) | 2018-10-23 | 2019-10-22 | Biaryl derivative |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022506017A JP2022506017A (ja) | 2022-01-17 |
JPWO2020086504A5 JPWO2020086504A5 (ja) | 2022-10-04 |
JP7449283B2 true JP7449283B2 (ja) | 2024-03-13 |
Family
ID=68542774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021520916A Active JP7449283B2 (ja) | 2018-10-23 | 2019-10-22 | ビアリール誘導体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11932600B2 (ja) |
EP (1) | EP3870287A1 (ja) |
JP (1) | JP7449283B2 (ja) |
KR (1) | KR20210080416A (ja) |
CN (1) | CN112912139B (ja) |
BR (1) | BR112021007261A2 (ja) |
CA (1) | CA3113805C (ja) |
TW (1) | TWI828783B (ja) |
WO (1) | WO2020086504A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015508102A (ja) | 2012-02-22 | 2015-03-16 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Tnap阻害剤としてのスルホンアミド化合物およびその使用 |
WO2017007943A1 (en) | 2015-07-08 | 2017-01-12 | Daiichi Sankyo Company, Limited | Pyrido-oxazinone derivatives as tnap inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2433496A1 (en) | 2007-05-08 | 2012-03-28 | Burnham Institute for Medical Research | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification |
MX2013014326A (es) | 2011-06-20 | 2014-01-23 | Du Pont | Compuestos heterociclicos para tratar infecciones por helmintos. |
EP3076968B1 (en) | 2013-12-02 | 2019-04-17 | ChemoCentryx, Inc. | Ccr6 compounds |
CN108484584A (zh) * | 2018-05-22 | 2018-09-04 | 窦玉玲 | 一种磺酰胺类衍生物及其在防治贫血药物中的用途 |
-
2019
- 2019-10-22 WO PCT/US2019/057314 patent/WO2020086504A1/en unknown
- 2019-10-22 JP JP2021520916A patent/JP7449283B2/ja active Active
- 2019-10-22 TW TW108138032A patent/TWI828783B/zh active
- 2019-10-22 CA CA3113805A patent/CA3113805C/en active Active
- 2019-10-22 KR KR1020217013739A patent/KR20210080416A/ko active Search and Examination
- 2019-10-22 EP EP19802372.3A patent/EP3870287A1/en active Pending
- 2019-10-22 BR BR112021007261-6A patent/BR112021007261A2/pt unknown
- 2019-10-22 CN CN201980069772.1A patent/CN112912139B/zh active Active
- 2019-10-22 US US17/287,445 patent/US11932600B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015508102A (ja) | 2012-02-22 | 2015-03-16 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Tnap阻害剤としてのスルホンアミド化合物およびその使用 |
WO2017007943A1 (en) | 2015-07-08 | 2017-01-12 | Daiichi Sankyo Company, Limited | Pyrido-oxazinone derivatives as tnap inhibitors |
Non-Patent Citations (1)
Title |
---|
Journal of Medicinal Chemistry,2009年,52(21),P.6919-6925 |
Also Published As
Publication number | Publication date |
---|---|
TW202030181A (zh) | 2020-08-16 |
WO2020086504A1 (en) | 2020-04-30 |
US11932600B2 (en) | 2024-03-19 |
TWI828783B (zh) | 2024-01-11 |
CA3113805A1 (en) | 2020-04-30 |
EP3870287A1 (en) | 2021-09-01 |
CA3113805C (en) | 2023-03-28 |
US20210355087A1 (en) | 2021-11-18 |
BR112021007261A2 (pt) | 2021-08-10 |
JP2022506017A (ja) | 2022-01-17 |
CN112912139B (zh) | 2024-07-09 |
CN112912139A (zh) | 2021-06-04 |
KR20210080416A (ko) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI689490B (zh) | 用於治療纖維化之經取代之芳族化合物及相關方法 | |
JP6859323B2 (ja) | カルボキシ置換(ヘテロ)芳香環誘導体並びにその調製方法及び使用 | |
CN104262330A (zh) | 新型脲取代联苯类化合物及其组合物及用途 | |
TW201808284A (zh) | 用於治療或預防高尿酸血症或痛風的化合物及其用途 | |
EP3793992B1 (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
EP3162801B1 (en) | Salt of halogen-substituted heterocyclic compound | |
KR102005068B1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
CA3163566A1 (en) | Processes for preparing triazole glycolate oxidase inhibitors | |
JP2024122966A (ja) | 芳香族化合物およびその医薬用途 | |
EP2867215B1 (en) | Tetrazole derivatives and their use as potassium channel modulators | |
JP7449283B2 (ja) | ビアリール誘導体 | |
US10464883B2 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
ES2965041T3 (es) | Composiciones para el tratamiento de la fibrosis pulmonar | |
US20190270698A1 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
WO2017030983A1 (en) | Compositions and methods for inhibition of cathepsins | |
US10183908B2 (en) | Compositions for the treatment of kidney and/or liver disease | |
KR20200026120A (ko) | 치환된 인돌 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 PPARα, PPARγ 및 PPARδ 관련 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220926 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240220 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240301 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7449283 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |